IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION
Case Number:
2:13-md-02445
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
-
October 30, 2017
Drug Developer Must Face Suboxone Product-Hopping Claims
A Pennsylvania federal judge found that sufficient evidence supports allegations that drug delivery developer MonoSol Rx LLC engaged in an anti-competitive scheme to delay generic versions of an opioid addiction treatment, rejecting the company's bid to toss the suit brought by more than 40 states Monday.
-
October 26, 2017
Parent Company Escapes Suboxone Product-Hop Suit
A Pennsylvania federal judge dismissed civil claims by more than 40 states against one of several companies accused of attempting to delay a generic version of an opioid addiction treatment, ruling Wednesday that the company didn't exist at the relevant time and thus cannot be held liable.
-
September 08, 2017
UK Drugmaker Can't Dodge States' Suboxone Case Just Yet
A Pennsylvania federal judge on Friday refused to dismiss a case brought by more than 40 states in multidistrict litigation accusing a U.K.-based drugmaker of delaying the introduction of generics of its opioid addiction treatment Suboxone, ruling that at the current stage in the case, the states have properly alleged their claims.
-
January 31, 2017
Indivior Must Face Suboxone Product-Hop Suit, States Say
More than 40 states suing Indivior PLC in a Pennsylvania federal court over allegations of delaying the introduction of a generic competitor to Suboxone argued Monday that a recent Third Circuit decision on product hopping does not support dismissing the suit.
-
January 04, 2017
Amneal Sees Key Suboxone Product-Hopping Claims Advance
A Pennsylvania federal judge on Wednesday advanced the bulk of generic-drug manufacturer Amneal's claims in its suit accusing drugmaker Indivior PLC of embarking on a product-hopping scheme to stave off generic competition to the opiate addiction treatment Suboxone.
-
December 13, 2016
Indivior Wants States' Suboxone Product-Hop Claims Nixed
Indivior Inc. asked a Pennsylvania federal court Monday to ax claims brought by more than 40 states that allege the company unlawfully stifled generic competition for opiate addiction treatment Suboxone, saying circuit courts have dismissed similar product-hopping allegations.
-
September 07, 2016
Buyer Must Give Up Suboxone Docs In Product-Hopping MDL
A Pennsylvania federal court on Tuesday ordered Burlington Drug Company Inc. to provide the maker of opiate addiction treatment Suboxone with downstream sales documents as part of multidistrict litigation over the use of "product hopping" to stifle competition, but said three other direct purchasers didn't have to produce such documents.
-
August 16, 2016
Suboxone Maker Says Docs Are Withheld In Product-Hop MDL
The maker of opiate addiction treatment Suboxone urged a Pennsylvania federal court Monday to enforce a court order directing wholesalers and others to produce downstream sales documents in multidistrict litigation accusing the drugmaker of "product hopping" to stifle competition from generics.
-
June 28, 2016
Indivior Scores Docs In Suboxone Product-Hopping MDL
Drug wholesalers and others accusing Indivior of product-hopping to stifle competition from generics of the Reckitt Benckiser spinoff's opiate addiction treatment Suboxone must produce downstream sales documents because they may be relevant to liability issues, a Pennsylvania federal judge ruled Tuesday.
-
June 24, 2016
Actavis Opposes Further Doc Production In Suboxone MDL
Actavis PLC on Thursday asked a Pennsylvania federal court to deny a motion for it to hand over documents in response to a third-party subpoena, saying that it has already produced the information requested by direct purchasers of Suboxone in multidistrict litigation accusing manufacturer Indivior PLC of engaging in a product-hopping scheme.